BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9059069)

  • 21. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
    Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
    Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports.
    Manfredi R; Mastroianni A; Coronado OV; Chiodo F
    Recenti Prog Med; 1996 Nov; 87(11):545-8. PubMed ID: 9122537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Should recurrent Cytomegalovirus infections in patients with liver transplantation be treated?].
    Tarp BD; Astrup LB
    Ugeskr Laeger; 1997 May; 159(22):3413-6. PubMed ID: 9199030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective pre-emptive therapy with Ganciclovir and specific immunoglobulins for CMV infection in a bone marrow transplanted patient.
    Dentamaro T; Volpi A; Cudillo L; Masi M; Tribalto M; Sordillo P; Salanitro A; Papa G
    Haematologica; 1992; 77(3):284-6. PubMed ID: 1330849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia.
    Zomas A; Mehta J; Powles R; Treleaven J; Iveson T; Singhal S; Jameson B; Paul B; Brincat S; Catovsky D
    Bone Marrow Transplant; 1994 Nov; 14(5):799-803. PubMed ID: 7889013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
    Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
    Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation.
    Drobyski WR; Knox KK; Carrigan DR; Ash RC
    Transplantation; 1991 Jul; 52(1):155-7. PubMed ID: 1650043
    [No Abstract]   [Full Text] [Related]  

  • 36. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
    Ljungman P; Oberg G; Aschan J; Ehrnst A; Lönnqvist B; Pauksen K; Sulila P
    Bone Marrow Transplant; 1996 Sep; 18(3):565-8. PubMed ID: 8879618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence and persistence of multiple antiviral-resistant CMV strains in a highly immunocompromised child.
    Iwasenko JM; Scott GM; Ziegler JB; Rawlinson WD
    J Clin Virol; 2007 Oct; 40(2):152-5. PubMed ID: 17698411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.
    Ohta H; Matsuda Y; Tokimasa S; Sawada A; Kim JY; Sashihara J; Amo K; Miyagawa H; Tanaka-Taya K; Yamamoto S; Tano Y; Aono T; Yamanishi K; Okada S; Hara J
    Bone Marrow Transplant; 2001 Jun; 27(11):1141-5. PubMed ID: 11551024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests.
    Fica A; Cervera C; Pérez N; Marcos MA; Ramírez J; Linares L; Soto G; Navasa M; Cofan F; Ricart MJ; Pérez-Villa F; Pumarola T; Moreno A
    Transpl Infect Dis; 2007 Sep; 9(3):203-10. PubMed ID: 17511827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recovery from CMV esophagitis after allogeneic bone marrow transplantation using non-myeloablative conditioning: the role of immunosuppression.
    Fiegl M; Gerbitz A; Gaeta A; Campe H; Jaeger G; Kolb HJ
    J Clin Virol; 2005 Nov; 34(3):219-23. PubMed ID: 16129661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.